In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non-small cell lung cancer cell lines

Oncology Reports

Volumn 33, Issue 1, 2015, Pages 239-249

  Wang, Min Cong ^a   Liang, Xuan ^a   Liu, Zhi Yan ^a,b   Cui, Jie ^a,c   Liu, Ying ^a   Jing, Li ^a   Jiang, Li Li ^a   Ma, Jie Qun ^a   Han, Li Li ^a   Guo, Qian Qian ^a   Yang, Cheng Cheng ^a   Wang, Jing ^a   Wu, Tao ^a   Nan, Ke Jun ^a   Yao, Yu ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b Zhongxin Hospital   (China)

^c Department of Anesthesiology Yanan University Affiliated Hospital   (China)

Author keywords

Chemotherapy; Epidermal growth factor receptor; Icotinib; Non small cell lung cancer; Sequentially combined

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ICOTINIB; PACLITAXEL; ANTINEOPLASTIC AGENT; CROWN ETHER; EGFR PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

A549 CELL LINE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE; CELL CYCLE G0 PHASE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG POTENTIATION; EGFR GENE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE MUTATION; H1299 CELL LINE; H1975 CELL LINE; HCC827 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR MECHANICS; NON SMALL CELL LUNG CANCER; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; IC50; LUNG TUMOR; METABOLISM; NUCLEOTIDE SEQUENCE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; CROWN ETHERS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; G0 PHASE; HUMANS; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; PACLITAXEL; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84916202468     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3583     Document Type: Article

References (41)

1. Jemal A, Thun MJ, Ries LA, et al: Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100: 1672-1694, 2008.
2. Reungwetwattana T, Weroha SJ and Molina JR: Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clin Lung Cancer 13: 252-266, 2012.
3. Salama JK and Vokes EE: New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. J Clin Oncol 31: 1029-1038, 2013.
4. Xu Y, Zhang Y and Ma S: EGFR inhibitors with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer. Lung Cancer 73: 249-255, 2011.
5. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl J Med 346: 92-98, 2002.
6. Smit EF, van Meerbeeck JP, Lianes P, et al: Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 21: 3909-3917, 2003.
7. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl J Med 350: 2129-2139, 2004.
8. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
9. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311, 2004.
10. Brandao GD, Brega EF and Spatz A: The role of molecular pathology in non-small-cell lung carcinoma-now and in the future. Curr Oncol 19 (Suppl 1): S24-S32, 2012.
11. Mitsudomi T and Yatabe Y: Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 277: 301-308, 2010.
12. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New Engl J Med 361: 947-957, 2009.
13. Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121-128, 2010.
14. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. New Engl J Med 362: 2380-2388, 2010.
15. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. New Engl J Med 353: 123-132, 2005.
16. Mok TS, Wu YL, Yu CJ, et al: Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 27: 5080-5087, 2009.
17. Giaccone G, Herbst RS, Manegold C, et al: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22: 777-784, 2004.
18. Herbst RS, Giaccone G, Schiller JH, et al: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22: 785-794, 2004.
19. Herbst RS, Prager D, Hermann R, et al: TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23: 5892-5899, 2005.
20. Davies AM, Ho C, Lara PN Jr, Mack P, Gumerlock PH and Gandara DR: Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer 7: 385-388, 2006.
21. Gandara DR and Gumerlock PH: Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out? J Clin Oncol 23: 5856-5858, 2005.
22. Normanno N: Gefitinib and cisplatin-based chemotherapy in non-small-cell lung cancer: simply a bad combination? J Clin Oncol 23: 928-930, 2005.
23. Baselga J: Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact? J Clin Oncol 22: 759-761, 2004.
24. Milano G, Spano JP and Leyland-Jones B: EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality. Br J Cancer 99: 1-5, 2008.
25. Zhao Q, Shentu J, Xu N, et al: Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer 73: 195-202, 2011.
26. Shi Y, Zhang L, Liu X, et al: Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol 14: 953-961, 2013.
27. Xu JM, Azzariti A, Colucci G and Paradiso A: The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines. Cancer Chemother Pharmacol 52: 442-448, 2003.
28. Cheng H, An SJ, Dong S, et al: Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib. J Hematol Oncol 4: 5, 2011.
29. Cheng H, An SJ, Zhang XC, et al: In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines. Cancer Chemother Pharmacol 67: 637-646, 2011.
30. Tsai CM, Chen JT, Stewart DJ, et al: Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed? J Thorac Oncol 6: 559-568, 2011.
31. Gandara D, Narayan S, Lara PN Jr, et al: Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer. Clin Cancer Res 11: 5057s-5062s, 2005.
32. Li T, Ling YH, Goldman ID and Perez-Soler R: Scheduledependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 13: 3413-3422, 2007.
33. Gumerlock PH, Pryde BJ, Kimura T, et al: Enhanced cytotoxicity of docetaxel OSI-774 combination in non-small cell lung carcinoma (NSCLC). J Clin Oncol 22: 2661, 2003.
34. Mahaffey CM, Davies AM, Lara PN Jr, et al: Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Clin Lung Cancer 8: 548-553, 2007.
35. Stewart DJ, Raaphorst GP, Yau J and Beaubien AR: Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis. Invest New Drugs 14: 115-130, 1996.
36. Stewart DJ: Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 63: 12-31, 2007.
37. Hall MD, Okabe M, Shen DW, Liang XJ and Gottesman MM: The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 48: 495-535, 2008.
38. Stewart DJ: Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol 75: 173-234, 2010.
39. Citri A and Yarden Y: EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7: 505-516, 2006.
40. Ciardiello F and Tortora G: EGFR antagonists in cancer treatment. New Engl J Med 358: 1160-1174, 2008.
41. Van Schaeybroeck S, Kyula J, Kelly DM, et al: Chemotherapyinduced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. Mol Cancer Ther 5: 1154-1165, 2006.